Sucampo Pharmaceuticals Fund Company Profile

Description

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product candidates, which are in clinical development stage comprise Cobiprostone that is in Phase IIa trials for the treatment of oral mucositis, non-erosive reflux, and symptomatic gastroesophageal reflux diseases; RTU-1096, which has completed Phase I trial for treating inflammation/immune-related disorders; and RTU-009 that is in development stage for inflammation/immune-related disorders, as well as CPP-1X/sulindac combination product, which is in phase III clinical trial for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals, Inc. is a subsidiary of S&R Technology Holdings, LLC.